Study wrapper · #865
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss.
Editor's note
A retrospective analysis of nearly 47,000 patients found semaglutide's cardiovascular benefit tracked more closely with attained dose than with achieved weight loss, supported by transcriptomic evidence of GLP1R expression in cardiac tissue. The dissociation from weight loss is an intriguing mechanistic argument for a direct cardiac effect, but the design is observational, dose and adherence are entangled with healthier-patient confounders, and the near-perfect dose-weight correlation complicates attribution. Noteworthy and hypothesis-generating, best read as a signal rather than settled causation.
Plain-language abstract
In a large records-based study, the heart benefits of semaglutide tracked more with the dose people reached than with how much weight they lost, hinting the drug helps the heart through routes beyond weight loss.